a4b7 Integrin in Eosinophilic Esophagitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02546219|
Recruitment Status : Completed
First Posted : September 10, 2015
Last Update Posted : February 21, 2019
|Condition or disease||Intervention/treatment|
|Eosinophilic Esophagitis||Other: Eosinophil isolation and characterization.|
|Study Type :||Observational|
|Actual Enrollment :||16 participants|
|Official Title:||Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis|
|Actual Study Start Date :||March 2016|
|Actual Primary Completion Date :||December 31, 2018|
|Actual Study Completion Date :||December 31, 2018|
Adults with EoE
Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
Other: Eosinophil isolation and characterization.
Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
- Percentage of eosinophils expressing a4b7 integrin [ Time Frame: 8 weeks ]Eosinophil expression levels of a4b7 integrin will be assessed on peripheral and esophageal eosinophils during active EoE and after treatment-induced remission.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02546219
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||John J Garber, MD||Massachusetts General Hospital|